|
|
|
|
|
|
Sponsors and Collaborators: |
Radiation Therapy Oncology Group National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00566852 |
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
PURPOSE: This randomized phase III trial is studying memantine to see how well it works compared to a placebo in preventing side effects caused by whole-brain radiation therapy in patients with brain metastases from solid tumors.
Condition | Intervention | Phase |
Brain and Central Nervous System Tumors Cognitive/Functional Effects Neurotoxicity Unspecified Adult Solid Tumor, Protocol Specific |
Drug: memantine hydrochloride Drug: placebo Procedure: radiation therapy |
Phase III |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Memantine Memantine hydrochloride |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Double-Blind, Placebo Control |
Official Title: | A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy |
Estimated Enrollment: | 536 |
Study Start Date: | March 2008 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Arm I: Experimental
Patients undergo whole-brain radiotherapy (WBRT) 5 days a week for 3 weeks (15 fractions). Patients also receive oral memantine hydrochloride once daily beginning on day 1 of WBRT and continuing for 24 weeks.
|
Drug: memantine hydrochloride
Given orally
Procedure: radiation therapy
Patients undergo whole-brain radiotherapy (WBRT) 5 days a week for 3 weeks.
|
Arm II: Active Comparator
Patients undergo WBRT as in arm I. Patients also receive oral placebo once daily beginning on day 1 of WBRT and continuing for 24 weeks.
|
Drug: placebo
Given orally
Procedure: radiation therapy
Patients undergo whole-brain radiotherapy (WBRT) 5 days a week for 3 weeks.
|
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study. Patients are stratified according to recursive partitioning analysis (RPA) prognostic class (class I vs class II with controlled systemic disease) and prior surgical therapy (none vs radiosurgery or surgical resection). Patients are randomized to 1 of 2 treatment arms.
After completion of study treatment, patients are followed at 6 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed diagnosis of a solid tumor malignancy within the past 5 years
Brain metastases must be visible on contrast-enhanced MRI or a contrast enhanced CT scan (for patients unable to undergo MRI within the past 28 days)
PATIENT CHARACTERISTICS:
Inclusion
Exclusion
Severe, active co-morbidity, defined as follows:
PRIOR CONCURRENT THERAPY:
Inclusion
Exclusion
Prior cranial radiotherapy
Show 53 Study Locations |
Radiation Therapy Oncology Group |
National Cancer Institute (NCI) |
Study Chair: | Paul D. Brown, MD | Mayo Clinic |
Investigator: | Christina A. Meyers, PhD | M.D. Anderson Cancer Center |
Investigator: | Sherry Fox, RN, PhD | Bon Secours Cancer Institute at St. Mary's Hospital |
Investigator: | Deepak Khuntia, MD | University of Wisconsin, Madison |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000577872, RTOG-0614 |
First Received: | December 1, 2007 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00566852 |
Health Authority: | Unspecified |
|
|
|
|
|